BioNTech SE and Shanghai Fosun Pharmaceutical (Fosun Pharma) has signed an agreement on Dec 16 to supply mainland China with 100 million doses of their BNT162 mRNA-based Covid-19 vaccine in 2021.

The initial supply will be delivered from BioNTech’s production facilities in Germany.

BioNTech and Fosun Pharma previously announced their strategic collaboration in March 2020 to jointly work on the development and commercialisation of a potential Covid-19 vaccine based on the former’s mRNA technology platform.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook